<DOC>
	<DOCNO>NCT02160665</DOCNO>
	<brief_summary>The purpose study compare safety efficacy profile Tazarotene Cream , 0.05 % Tazorac® ( Tazarotene ) Cream , 0.05 % order demonstrate bioequivalence demonstrate superiority 2 active cream Vehicle ( placebo ) treatment plaque psoriasis .</brief_summary>
	<brief_title>Generic Tazarotene Cream , 0.05 % Treatment Plaque Psoriasis</brief_title>
	<detailed_description>This double-blind , randomize , parallel-group , vehicle-controlled , multicenter study Tazarotene Cream , 0.05 % subject plaque psoriasis . Subjects randomly assign 1:1:1 ratio Test , Reference , Vehicle . Subjects admit study inform consent obtain inclusion/exclusion criterion meet . At visit , investigator ( whenever possible ) grade clinical sign plaque psoriasis designate target lesion site use Psoriasis Area Severity Index ( PASI ) , Investigator 's Global Assessment ( IGA ) disease severity perform ( IGA score range 0 = none 5 = severe ) , application site reaction ( erythema , dryness , burning/stinging , erosion , edema , pain , pruritus ) assess . In addition , involve body surface area ( BSA ) determine Visit 1 Visit 4 . Safety assess monitoring adverse event ( AEs ) visit telephone contact Day 7 ( + 4 day )</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Be willing able provide write informed consent study 2 . Be male female , least 18 year age 3 . Have definite clinical diagnosis stable ( least 6 month ) plaque psoriasis , involve least 2 % 20 % body surface area ( BSA ) ( include scalp intertriginous area ) 4 . Have minimum plaque elevation target lesion site least moderate severity ( grade ≥ 3 Psoriasis Area Severity Index [ PASI ] ) . The severe lesion baseline identify target lesion 5 . Have Investigator 's Global Assessment ( IGA ) disease severity least moderate ( score ≥ 3 ) overall assessment lesion treat . 6 . Be general good health free clinically significant disease psoriasis might interfere study evaluation 7 . Be willing able understand comply requirement study , apply study medication instruct , return require treatment period visit , comply therapy prohibition , able complete study 8 . Female subject childbearing potential ( exclude woman surgically sterilize postmenopausal least 2 year ) must negative urine pregnancy test sensitivity least 50 mIU/ml hCG , begin treatment normal menstrual period must willing use acceptable method contraception study . The following consider acceptable method birth control purpose study : oral contraceptive , contraceptive patch , contraceptive implant , vaginal contraceptive , double barrier method ( e.g. , condom spermicide ) , contraceptive injection ( DepoProvera® ) , intrauterine device ( IUD ) , hormonal IUD ( Mirena® ) , abstinence document second acceptable method birth control subject become sexually active . Subjects enter study hormonal contraceptive must method least 90 day prior study continue method duration study . Subjects use hormonal contraception stop must stop less 90 day prior Visit 1/Day 1 9 . Be willing limit sun exposure overall , maintain reasonably constant exposure , avoid use tan booth UV light source participation study 1 . A female subject pregnant , nursing , plan pregnancy , agree use acceptable form birth control within study participation period 2 . Have current diagnosis unstable form psoriasis treatment area , include pustular , guttate , exfoliative erythrodermic psoriasis 3 . Have history psoriasis unresponsive topical treatment 4 . Have inflammatory skin disease treatment area may confound evaluation plaque psoriasis ( e.g. , atopic dermatitis , contact dermatitis , eczema , tinea corporis ) 5 . Have pigmentation , extensive scarring , pigmented lesion , sunburn treatment area could interfere rating efficacy parameter 6 . Have unstable medical disorder , lifethreatening disease , current malignancy 7 . Have current immunosuppression 8 . Have receive treatment list Table 8 1 recently indicate washout period prior Visit 1/Day 1 9 . Would continue receive treatment list Table 8 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>